Abstract 169P
Background
The TALENTop study (NCT04649489) is aiming to clarify whether hepatic resection may provide additional benefit in HCC patients with macrovascular invasion (MVI) who responded to conversion therapy with atezolizumab plus bevacizumab (atezo/bev). This study is onging and the primary analysis is expected at a later time; instead, this analyse is to demonstrate the conversion results of atezo/bev. To describe the response and safety outcomes of the conversion therapy and prognostic factors associated with being suitable for R0 hepatic resection.
Methods
HCC patients with MVI and without extrahepatic metastasis are eligible for this study. After received 3 cycles of atezo/bev and 1 cycle of atezo (induction phase), patients assessed as PR or SD (RECIST v1.1) and considered suitable for R0 hepatic resection are 1:1 randomized to Arm A, hepatic resection followed by atezo/bev for 1 year, or Arm B, continuing atezo/bev therapy. The primary endpoint is the time to treatment failure (tumor recurrence or progression or death). Treatment efficacy in the induction phase were analysed.
Results
From Apr 2021 to Dec 2022, 201 patients were enrolled and entered induction phase and completed induction phase therapy of atezo/bev at cut-off date (Apr 2023). The patients were characterized with a median age of 55 (26-78) and 187 (93%) had HBV infection. Mean tumor diameter evaluated by IRF is 100 mm (26-231 mm). All patients had MVI at baseline and 191 (95%) had PVTT. According to RECIST v1.1 criteria, 38 patients (18.9%) achieved PR and 106 patients (52.7%) achieved SD with 3 cycles of atezo/bev and 1 cycle of atezo. ORR and DCR were 18.9% and 71.6%, respectively. Grades ≥3 TRAEs occurred in 26 patients (12.9%). Most common TRAE was fever (13.4%) and proteinuria (10.9%). Of 201 patients, 73 patients (36.3%) were evaluated as suitable for R0 resection and randomized. In univariate logistic regression, PVTT with vp1-2, AFP<400ng/mL, NLR (neutrophil-lymphocyte ratio)<2.63, tumor diameter<100mm were associated with randomization.
Conclusions
Atezo/bev showed high response rate and conversion rate in the HCC patients with MVI, suggesting a promising conversion strategy in this population.
Clinical trial identification
NCT04649489.
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University.
Funding
Shanghai Roche Pharmaceuticals Ltd., China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract